ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

about

Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.

P2860

Q36081175-3CB5E553-A827-46E7-AA10-606BD9630AF4 Q39410543-8DD68A07-6762-4C74-B9C2-4535044E22FE

P2860

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

Item

http://www.wikidata.org/entity/Q36353183

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@ast

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@en

type

Item

label

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@ast

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@en

prefLabel

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@ast

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@en

P1476

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

@en

P2093

Abdalla Awidi

http://www.w3.org/2001/XMLSchema#string

Ahmad Magablah

http://www.w3.org/2001/XMLSchema#string

Lina Marei

http://www.w3.org/2001/XMLSchema#string

Nazzal Bsoul

http://www.w3.org/2001/XMLSchema#string

Nidaa Ababneh

http://www.w3.org/2001/XMLSchema#string

Razan Mefleh

http://www.w3.org/2001/XMLSchema#string

Salah Abbasi

http://www.w3.org/2001/XMLSchema#string

P2860

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Chronic myelogenous leukemia.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

Resistance to imatinib mesylate in chronic myeloid leukaemia.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.

P304

1317-1321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/GTMB.2012.0147

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23009571

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

3483047

http://www.w3.org/2001/XMLSchema#string

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

about

P2860

P2860

ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932